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Available online 6 September 2007AbstractNeoplasms originating from plasma cell are rare in the head and neck region. A correct clinical evaluation is very important in order to
formulate a differential diagnosis as well as to distinguish local from metastatic disease. We report a case of larynx involvement by an IgA
multiple myeloma in a 69-year-old female diagnosed in October 2004 and treated with chemotherapy; the 1 year control do not show
progression of disease and the laryngeal lesion is unchanged. We highlight the radiological findings and clinical features to suspect plasma cell
tumors in cases with a similar presentation.
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Neoplasms originating from plasma cell are rare in the
head and neck region. They arise as a monoclonal
proliferation of plasma cells during their various stage of
differentiation (classified as a peripheral B-cell neoplasm in
a revised European-American classification [1]). The
clinical classification divides these neoplasm into three
types: multiple myeloma (MM), solitary plasmacytoma of
bone (SPB) and extramedullary plasmacytoma (EMP).
A correct clinical evaluation is very important in order to
make the correct diagnosis as well as to distinguish this kind
of tumor and the extent of disease, to institute the correct
treatment and to estimate survival time. A plasma cell tumor
classified as a solitary plasmacytoma of bone if evidenced in
bone; in soft tissue as a extramedullary plasmacytoma, while
the systemic form of the disease is called multiple myeloma.
These three clinical entities are considered as represent-
ing distinct manifestations of a continuum of disease. About
20–30% of EMP may progress to a MM [2].* Corresponding author. Tel.: +39 03334565471.
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doi:10.1016/j.anl.2007.04.011We report the clinical and radiological features of a
patient affected by IgA MM with laryngeal involvement,
treated by chemotherapy; we outline the importance of
differential diagnosis considering also this rare entity.2. Case report
A 69-year-old woman affected by high-plasma level of IgA
was diagnosed with a monoclonal gammopathy of undeter-
mined significance (MGUS). She experienced progressive
hoarseness and slight dysphagia. The patient did not complain
of dyspnea nor did she have risk factors for laryngeal cancer
(smoking and alcohol). She had no previous intubation,
trauma or surgical procedures. She was a type II diabetic with
hypertension, both efficiently controlled by medical therapy.
Indirect laryngoscopic examination revealed sub-muco-
sal swelling of the right ventricular fold (false cord),
ventricle and true vocal cord, reduction of right side motility,
normal mucosa (Fig. 1). A mass in the right thyroid ala was
found during neck examination; after a CT scan without
contrast enhancement of the neck, a structural alteration
within thyroid cartilage in right ala with cortical thinning
and right supraglottic and concentric cricoid ring thickness
was evidenced (Fig. 2)..
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Fig. 1. Indirect laryngoscopic examination show a sub-mucosal swelling of
right false cord, ventricle and true vocal cord and normal mucosal surface.Biopsy of the mucosa and sub-mucosal layer was
performed under direct microlaryngoscopy. Histopathology
demonstrated a diffuse massive infiltration of plasma cells.
Haematological consultation was sought in order to
further assess the nature of the disease. Serum and urine
electrophoresis was performed which confirmed the
previous findings of a high-plasma level of monoclonal
IgA; bone marrow biopsy revealed plasma cell infiltration of
20%. Routine laboratory tests showed anaemia (haemoglo-
bin 8.9 g/dl; RBC 2,980,000/mmc; WBC 3200/mmc;
plasmatic albumin 3.5 g/dl, beta-2-microglobulin 5.6 g/dl).
All these findings affirmed the diagnosis of MM stage IIIa.
The patient underwent chemotherapy with VAD protocol
(vincristine, doxorubicin and dexamethasone) for a total of 4Fig. 2. CT scan of larynx without contrast enhancement showing a struc-
tural alteration within thyroid cartilage in right ala with cortical thinness.cycles; 1-year clinical and radiological follow-up did not
show progression of disease with the laryngeal involvement
unchanged.3. Discussion
Laryngeal involvement in patients affected by MM is rare
and few cases are reported in literature [3–9].
Two pathogenetics mechanisms are postulated by several
authors to explain the involvement of laryngeal cartilage: (1)
cartilage may be involved by an adjacent plasmacytoma; (2)
cartilage, particularly in older people, may undergo to
osseous metaplasia with formation of central marrow space,
therefore a plasmacytoma may directly originate from this
bone marrow [10]. Thyroid cartilage expansion and
destruction evidenced in the CT scans suggests as in our
case a myelomatous involvement of extraskeletal bone
marrow formed by osseous metaplasia [8].
Consideration of this process is mandatory considering
that laryngeal involvement in EMP is between 5% and 18%
[11–13] with different treatment and with a better prognosis
than MM. As a matter of fact EMP may evolve to MM many
months or years later after diagnosis [14,15]. When a plasma
cell tumor involving the larynx is diagnosed the next step is
to exclude systemic disease. The patient must undergo
detection of monoclonal gammopathy in serum or urine, a
bone marrow aspiration biopsy and complete radiological
examination in order to demonstrate osteolytic bone lesions.
Diagnosis of MM is based on: histological evidence of
plasmacytoma or plasmacytosis in bone marrow; clinical
signs of disease such as bone pain, anaemia and renal failure;
detection of the monoclonal gammopathy in serum or urine
and demonstration of osteolytic bone lesion. EMP and SBP
are diagnosed if plasmacytoma is present in soft tissue or
bone with no dissemination of disease.
Involvement of the thyroid cartilage is very rare [8,9]. CT
examination can demonstrate a typical pattern: thinning and
expansion of the lamina of the thyroid ala (as in our case),
thus confirming its origin within the thyroid structure caused
by osseous metaplasia of the cartilage [8]. Treatment of
different form of plasma cells tumors is related to their
extension: EMP and SBP can be treated by external radiation
therapy with 40–50 Gy for a 4-week period including
cervical lymph nodes in order to prevent lymph node
recurrences [16]. Surgical removal is a second line treatment
particularly in case of salvage therapy after radiation failure.
The treatment of symptomatic patients affected by MM,
even with larynx involvement, involves chemotherapy or
bone marrow transplantation. Surgery is mainly diagnostic
in the majority of cases and tracheotomy is performed in
case of airway obstruction.
Usually plasma cell neoplasms appear in the elderly
while MM variant about 10 years later than the others two.
After diagnosis MM have a mean survival of about 2–3
years, while EMP and SPB have a better prognosis.
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Plasma cell neoplasms are unusual in the head and neck
region and are histologically indistinguishable because they
represent a continuum disease, as illustrated by progression
of EMP and SPB to MM. The diagnosis is made on the basis
of clinical, radiological and pathological findings, and the
distinction between EMP, SPB and MM is critical for
treatment and survival. In the case of typical CT scan larynx
pattern a plasma cell tumor must be suspected for correct
management.References
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